Impact of Concomitant Metamizole Treatment on the Exposure of Mould‐Active Triazoles
Mycoses · 2026-05 · 69 (5)
DOI: 10.1111/myc.70173 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mycoses, online erschienen am 14.05.2026. Verfasst von Dorian Vanneste und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Dipyrone, Triazoles, Antifungal Agents, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim
Metamizole is an analgesic drug with moderate cytochrome P450 (CYP) inductive properties. The antifungal triazoles are metabolized by several CYP enzymes, but the interaction with metamizole remains poorly described. We investigated the influence of metamizole on the exposure of voriconazole, isavuconazole, and posaconazole.
Methods
Patients from UZ Leuven (Belgium) and Ljubljana University Medical Centre (Slovenia) receiving voriconazole, isavuconazole, or posaconazole concomitantly with metamizole were included in the study. Routine therapeutic drug monitoring (TDM) measurements collected between January 2019 and December 2024 were retrieved retrospectively. TDM concentrations outside of concomitant therapy were collected as controls. The influence of metamizole and other clinically relevant covariates was analysed using generalized estimating equations (GEE).
Results
A total of 126 distinct treatments with a triazole from 115 patients, accounting for 392 measurements, were included in the study. GEE analysis revealed a significant negative association between the 7‐day cumulative metamizole dose and lower voriconazole and posaconazole concentrations. Additionally, C‐reactive protein had a positive association with voriconazole concentrations. Only ICU admission and patient characteristics, that is, sex and weight, had a significant influence on isavuconazole concentrations.
Conclusion
Concomitant therapy with metamizole led to lower voriconazole and posaconazole concentrations, presumably through induction of CYP enzymes and possibly UDP‐glucuronyltransferase. We recommend avoiding concomitant use of metamizole with the antifungal triazoles to prevent underexposure and treatment failure or frequent TDM if the combination cannot be avoided. Further studies are needed to confirm our findings and investigate the influence of metamizole on other triazoles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium.
- Department of Infectious Diseases, University Medical Center, Ljubljana, Slovenia.
- Institute of Clinical Chemistry and Biochemistry, University Medical Center Ljubljana, Slovenia.
- Pharmacy Department, University Hospitals Leuven, Leuven, Belgium.
- Grošelj Matos Otorinolaringologija, Ljubljana, Slovenia.
- Pharmacy Department, University Medical Centre, Ljubljana, Slovenia.
ORCID-Profile: Dorian Vanneste
Zitieren
APA
Vanneste, D., De Booser, I., Nadrah, K., Somrak, M., Gijsen, M., Matos, A., Kalan, K., Morlion, B., Rex, S., Battelino, S., Lagrou, K., Maertens, J., & Spriet, I. (2026). Impact of Concomitant Metamizole Treatment on the Exposure of Mould‐Active Triazoles. Mycoses, 69(5). https://doi.org/10.1111/myc.70173
Vancouver
Vanneste D, De Booser I, Nadrah K, Somrak M, Gijsen M, Matos A, et al. Impact of Concomitant Metamizole Treatment on the Exposure of Mould‐Active Triazoles. Mycoses. 2026;69(5). doi:10.1111/myc.70173
BibTeX
@article{Vanneste2026,
author = {Vanneste, Dorian and De Booser, Ine and Nadrah, Kristina and Somrak, Matej and Gijsen, Matthias and Matos, Aleš and Kalan, Katja and Morlion, Bart and Rex, Steffen and Battelino, Saba and Lagrou, Katrien and Maertens, Johan and Spriet, Isabel},
title = {Impact of Concomitant Metamizole Treatment on the Exposure of Mould‐Active Triazoles},
journal = {Mycoses},
year = {2026},
volume = {69},
number = {5},
doi = {10.1111/myc.70173}
}
EUVIMED